GRAIL Inc., a health care company whose mission is to detect cancer early, when it can be cured, recently announced the appointment of Gautam Kollu as Chief Commercial Officer.
“We are very pleased to welcome Gautam, who brings extensive experience in accelerating market development efforts to support the adoption of novel technologies in the genomics space,” said GRAIL CEO Hans Bishop. “It’s an exciting time for our company, and Gautam’s strategic leadership will be invaluable as we work to advance our multi-cancer early detection test toward commercialization.”
“I’m thrilled to join GRAIL in its bold pursuit to transform cancer care through early detection. I look forward to building a leading commercial organization in support of our first-of-kind multi-cancer early detection test and our mission to decrease the burden of cancer and save lives,” Kollu said.
Kollu joins GRAIL from Illumina, Inc., where he most recently served as vice president, global market development, and led the teams that drove the commercial adoption of genomics in multiple applications including noninvasive prenatal testing and liquid biopsy. Prior to his role at Illumina, Kollu served as vice president of marketing, medical affairs, and business development at Natera, Inc.; vice president of commercial at Exelixis, Inc.; and held multiple marketing and commercial roles at Genentech, Inc.
Read the full press release here.